Vision, Integrity, Expertise

Soligenix, Inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.

conference call icon 17th Annual BIO CEO Investor Conference
Soligenix Presentation Webcast

Tuesday, February 10, 2015 at 1:30 PM EST
Waldorf Astoria, New York City
 
Non Confidential Introduction
to ThermoVax™

January 2014

View the presentation (pdf)
Corporate Presentation
February 17, 2015


View the presentation (pdf)
 
Innate Defense Regulators as a Treatment for Melioidosis Presentation
February 2015


View the presentation (pdf)
Thermostable Subunit Vaccine Results in Protective Immunity in Rhesus Macaques in an Inhalational Ricin Model
February 2015

View the presentation (pdf)

Latest News
Friday, February 13, 2015
Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
Wednesday, February 11, 2015
Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
Thursday, February 05, 2015
Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City

See more news & events >

Partnering with Us

Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of HSC transplant, supportive cancer care, gastrointestinal and biodefense.

Learn More >